Mycardis, tablets 80 mg 28 pcs

Micardis is a hypotensive.

Blocks angiotensin II receptors (type AT₁) and eliminates its vasoconstrictor effect. Reduces systemic BP, plasma concentrations of aldosterone.

Pharmacokinetics

In oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 50%. In concomitant use with food the AUC decreases from 6% (at a dose of 40 mg) to 19% (at a dose of 160 mg). In 3 hours after the dose, plasma concentrations level off regardless of whether the drug is taken on an empty stomach or with food. C_max and AUC are 3 and 2 times higher in women compared to men, respectively, with no significant effect on concentration. Binding to plasma proteins is 99.5%, mainly to albumin and alpha₁ glycoprotein. Mean apparent volume of distribution in the equilibrium stage is 500 L. Metabolized by conjugation with glucuronic acid. Metabolites are pharmacologically inactive. T_1/2 is greater than 20 h. Total plasma Cl is high (900 ml/min) compared to hepatic blood flow (about 1500 ml/min). Excreted through the intestine unchanged, excretion by the kidneys is less than 2%.

The maximum effect develops 3 hours after a single dose. Hypotensive effect lasts more than 24 hours, including the last 4 hours before taking the next dose. Stable clinical result is reached after 4-8 weeks of course use and is long maintained. On abrupt discontinuation of therapy BP gradually (over several days) returns to baseline values without the manifestation of “ricochet” hypertension.

Indications

Arterial hypertension.

Pharmacological effect

Micardis – hypotensive.

Blocks angiotensin II receptors (AT1 type) and eliminates its vasoconstrictor effect. Reduces systemic blood pressure and plasma aldosterone concentration.

Pharmacokinetics

When taken orally, it is quickly absorbed from the gastrointestinal tract. Bioavailability – 50%. When taken concomitantly with food, the reduction in AUC ranges from 6% (at a dose of 40 mg) to 19% (at a dose of 160 mg). 3 hours after administration, the plasma concentration levels off regardless of taking the drug on an empty stomach or with food. Cmax and AUC are 3 and 2 times higher, respectively, in women compared to men, without a significant effect on concentration. Plasma protein binding is 99.5%, mainly with albumin and alpha1 glycoprotein. The average value of the apparent volume of distribution at the equilibrium stage is 500 l. Metabolized by conjugation with glucuronic acid. Metabolites are pharmacologically inactive. T1/2 – more than 20 hours. Total plasma Cl is high (900 ml/min) compared to hepatic blood flow (about 1500 ml/min). Excreted through the intestines unchanged, excretion by the kidneys is less than 2%.

The maximum effect develops 3 hours after a single dose. The hypotensive effect lasts more than 24 hours, including the last 4 hours before taking the next dose. A stable clinical result is achieved after 4–8 weeks of course use and is maintained for a long time. If you abruptly stop taking blood pressure, it gradually (over several days) returns to initial values ​​without the manifestation of “rebound” hypertension.

Special instructions

Effect on the ability to drive a car and machinery

No special studies have been carried out on the effect of the drug on the ability to drive a car or operate machinery.

However, when driving a car or using machinery, you should be aware of the possibility of dizziness and drowsiness when using drugs used to treat arterial hypertension.

Active ingredient

Telmisartan

Composition

Active ingredient:

telmisartan 80 mg;

Excipients:

polyvidone;

meglumine;

sodium hydroxide;

sorbitol;

magnesium stearate

Contraindications

Hypersensitivity, bile duct obstruction, severe liver or kidney dysfunction, hereditary fructose intolerance, pregnancy, breastfeeding, childhood and adolescence.

Side Effects

From the nervous system: headache, dizziness, fatigue, insomnia, anxiety, depression, convulsions.

From the respiratory system: upper respiratory tract infections (including pharyngitis, sinusitis, bronchitis), cough.

From the cardiovascular system: marked decrease in blood pressure, bradycardia, tachycardia, chest pain.

From the digestive system: nausea, dyspepsia, diarrhea, abdominal pain, increased activity of “liver” transaminases.

From the musculoskeletal system: myalgia, arthralgia, lower back pain, tendinitis-like symptoms.

From the urinary system: peripheral edema, urinary tract infections, hypercreatininemia.

Allergic reactions: skin rash, etc.

Laboratory indicators: rarely – hyperkalemia, anemia or hyperuricemia.

Other: influenza-like syndrome, rarely – erythema, itching, syncope, dyspnea, eosinophilia, thrombocytopenia, angioedema, urticaria.

Interaction

Thiazide diuretics (eg hydrochlorothiazide) enhance the hypotensive effect of telmisartan. Telmisartan enhances the hypotensive effect of other antihypertensive drugs and increases the concentration of digoxin in the blood.

Overdose

Symptoms: pronounced decrease in blood pressure.

Treatment: symptomatic therapy; hemodialysis is ineffective.

Storage conditions

In a dry place, at a temperature not exceeding 30 °C

Shelf life

4 years

Manufacturer

Boehringer Ingelheim Pharma GmbH & Co.KG, Germany